Skip to main content
NIH funding notice RFA-HG-20-015

Novel Synthetic Nucleic Acid Technology Development (R21 Clinical Trial not allowed)

Closed on February 4, 2022.

Posted
March 19, 2020
Close date
February 4, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $792,907 in first-year total cost, median $265,465.

Most frequent study sections

  1. Special Emphasis Panel[ZHG1 HGR-M (O1)]3

Most frequent institutions

  1. DUKE UNIVERSITY1
  2. STATE UNIVERSITY OF NEW YORK AT ALBANY1
  3. UNIVERSITY OF WISCONSIN-MADISON1
Competing awards under RFA-HG-20-015 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2022Automated CRISPR Enabled DNA Synthesis (CEDS)1R21HG011675-01A1LYNCH, MICHAEL DAVIDDUKE UNIVERSITY, NC$295,025ZHG1
2022GenSyn: A Cycle for Serial Assembly of Very Large DNA Molecules1R21HG012281-01SCHWARTZ, DAVID C.UNIVERSITY OF WISCONSIN-MADISON, WI$265,465ZHG1
2022Synthesis and non-chromatographic purification of long RNA oligonucleotides containing naturally occurring modification1R21HG012257-01ROYZEN, MAKSIMSTATE UNIVERSITY OF NEW YORK AT ALBANY, NY$232,417ZHG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-HG-20-015: Novel Synthetic Nucleic Acid Technology Development (R21 Clinical Trial not allowed) | ScienceDex | ConductScience